Skip to content
Search

Latest Stories

Submit Guest Post

Gully Boy actor Siddhant Chaturvedi reveals he had auditioned for Aladdin

Student Of The Year 2 actress Tara Sutaria had auditioned to play the role of Jasmine in Disney’s Aladdin. And now, here’s one more Indian actor who has auditioned to be a part of the Hollywood movie. We are talking about Siddhant Chaturvedi who impressed one and all with his performance as MC Sher in Zoya Akhtar’s Gully Boy.

Recently, while talking to a new agency, Siddhant revealed, "I had auditioned for the lead role in Aladdin. I was there in at least top 20 from India. This is for the role of Aladdin, they were looking for an Indian boy back then but then they decided the accent needs to be international. It was their call.”


"Then there was another film called Million Dollar Arm. I did audition for it as well, it was not for dubbing. They had two Indian guys who play baseball, I did the audition for that. They felt I was too upmarket and fair for it," the actor added.

Siddhant has dubbed for Chris Hemsworth in the Hindi version of MIB: International. Talking about it, the actor said, "I do believe we are no less than anyone else. It is a language barrier between two film industries - Hollywood and Bollywood and I want to break that barrier."

However, the young actor wants to concentrate on Hindi films right now. He said "I am an Indian actor but I want to do everything. At the moment I want to focus here (on Hindi films) but I am open to the idea of working there (West)."

Talking about being the voice of Chris Hemsworth, Siddhant said, "I was looking to sign my next film and was reading a lot of scripts. My agent called me and asked me if I would be interested to dub for Chris Hemsworth's character in his Hollywood film Men In Black. I almost choked. I am a huge fan of Chris, he is a superhero, he is Thor. I was thinking if I can match his manly, husky voice as he has a baritone. It was a challenge for me. And I started doing rehearsals for it.”

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

Moderna shares

Moderna's latest cancer trial has revived investor interest in its mRNA technology

iStock {Representational image}

Moderna shares nearly trebled after a cancer trial breakthrough: What changed?

  • Moderna shares jumped 177 per cent after the late-stage melanoma trial results.
  • The personalised treatment is designed around mutations found in each patient's tumour.
  • The result could give Moderna a new growth path as demand for its Covid vaccines has weakened.

Moderna has given investors something they have been waiting for since the Covid vaccine boom: a reason to believe its mRNA technology could become a much bigger business beyond infectious diseases.

Shares in the US drugmaker jumped 177 per cent to $174.38 on August 19 after Moderna and Merck reported positive results from a late-stage trial of an experimental personalised cancer treatment. It was Moderna's biggest one-day percentage gain since its 2018 stock market debut and added billions of dollars to its market value.

Keep ReadingShow less